Can losartan and blood pressure control peri arteriovenous fistula creation ameliorate the early associated left ventricular hypertrophic response a randomised placebo controlled trial

BMC Research Notes

Anuradha Aggarwal²  Matija Raspudic¹  Geoffrey Lee²  Athanasia Alexiou²  Alison Kinghorn²  Sofie Karapanagiotidis²  Anthony Yapanis²  Eugenie Pedagogos¹  Dominica Zentner² 

[1]Dept of Nephrology, Royal Melbourne Hospital, Grattan St, Parkville, 3050, Australia

[2]Dept of Cardiology, Royal Melbourne Hospital, Grattan St, Parkville, 3050, Australia

关键词: Haemodialysis;    Hypertrophy, Left ventricular;    Echocardiography, Transthoracic;    Blood pressure;    Arteriovenous fistula;   

Others  :  1166383
DOI  :  10.1186/1756-0500-5-260

 received in 2012-03-07, accepted in 2012-05-29,  发布年份 2012

【 摘 要 】

Background

Haemodialysis results in a left ventricular hypertrophic response. It is unclear whether tight blood pressure control or particular medications might attenuate this response. We sought to determine, in a pre-dialysis cohort on atenolol, whether Losartan might attenuate left ventricular hypertrophy post arteriovenous fistula creation in end stage kidney disease.

Materials and methods

Placebo controlled double blind randomisation of 26 patients to fixed dose atenolol plus fixed dose losartan or placebo occurred 1 day prior to fistula creation. Pre-randomisation echocardiography was repeated at 1 week and 1-month. Measurement was undertaken of blood pressure, heart rate, brain natriuretic peptide, serum creatinine and estimated glomerular filtration rate. The primary pre-specified endpoint was the change in left ventricular mass at 1 month. Non-parametric statistical comparison was performed within and between groups.

Results

There was no difference in left ventricular mass between our groups 1-month post fistula creation. In the entire cohort, change in left ventricular mass was driven by changes in blood pressure and volume loading. Blood pressure changes correlated with left ventricular mass changes seen shortly post arteriovenous fistula creation, suggesting blood pressure control during this time period may be an important part of the management of end stage kidney disease.

Conclusions

We did not see an advantage with the use of losartan with respect to diminution of the LVM response. However, our demonstrated change in LVM was relatively small compared to previous literature and suggests a possible role for beta blockade as a neurohormonal modulator around the time of arteriovenous fistula creation.

Trial registration

Clinical trials.gov (NCT00602004).

【 授权许可】

   
2012 Zentner et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Dyadyk OI, Bagriy AE, Yarovaya NF: Disorders of left ventricular structure and function in chronic uremia: how often, why and what to do with it? Eur J Hear Fail 1999, 1(4):327-336.
• [2]Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J: Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005, 68(2):788-795.
• [3]Movilli E, Viola BF, Brunori G, Gaggia P, Camerini C, Zubani R, Berlinghieri N, Cancarini G: Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: a prospective study. Am J Kidney Dis 2010, 55(4):682-689.
• [4]Meeus F, Kourilsky O, Guerin AP, Gaudry C, Marchais SJ, London GM: Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int Suppl 2000, 76:S140-S147.
• [5]Dikow R, Schwenger V, Zeier M, Ritz E: Do AV fistulas contribute to cardiac mortality in hemodialysis patients? Semin Dial 2002, 15(1):14-17.
• [6]MacRae JM: Vascular access and cardiac disease: is there a relationship? Curr Opin Nephrol Hypertens 2006, 15(6):577-582.
• [7]Iwashima Y, Horio T, Takami Y, Inenaga T, Nishikimi T, Takishita S, Kawano Y: Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002, 40(5):974-982.
• [8]Unger P, Velez-Roa S, Wissing KM, Hoang AD, van de Borne P: Regression of left ventricular hypertrophy after arteriovenous fistula closure in renal transplant recipients: a long-term follow-up. Am J Transplant 2004, 4(12):2038-2044.
• [9]van Duijnhoven EC, Cheriex EC, Tordoir JH, Kooman JP, van Hooff JP: Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients. Nephrol Dial Transplant 2001, 16(2):368-372.
• [10]Grassi G, Arenare F, Pieruzzi F, Brambilla G, Mancia G: Sympathetic activation in cardiovascular and renal disease. J Nephrol 2009, 22(2):190-195.
• [11]Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, et al.: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002, 105(11):1354-1359.
• [12]Eichhorn EJ, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996, 94:2285-2296.
• [13]Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, et al.: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
• [14]Ishiye M, Umemura K, Uematsu T, Nakashima M: Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload. Biol Pharm Bull 1995, 18(5):700-704.
• [15]Mitsuhashi H, Tamura K, Yamauchi J, Ozawa M, Yanagi M, Dejima T, Wakui H, Masuda S, Azuma K, Kanaoka T, et al.: Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009, 207(1):186-190.
• [16]Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T: Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002, 90(3):256-261.
• [17]Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M: Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002, 20(9):1855-1864.
• [18]Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993, 44(4):881-886.
• [19]Ori Y, Korzets A, Katz M, Perek Y, Zahavi I, Gafter U: Haemodialysis arteriovenous access–a prospective haemodynamic evaluation. Nephrol Dial Transplant 1996, 11(1):94-97.
• [20]Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al.: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
• [21]Daniels LB, Maisel AS: Natriuretic peptides. J Am Coll Cardiol 2007, 50(25):2357-2368.
• [22]Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ: B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005, 46(4):610-620.
• [23]Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, et al.: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001, 12(7):1508-1515.
• [24]Korsheed S, Eldehni MT, John SG, Fluck RJ, McIntyre CW: Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 2011, 26(10):3296-302. 10.1093/ndt/gfq851
• [25]Gosse P: Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005, 23(1):S27-33.
• [26]Paoletti E, Specchia C, Di Maio G, Bellino D, Damasio B, Cassottana P, Cannella G: The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004, 19(7):1829-1834.
• [27]Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002, 144(6):1057-1064.
• [28]Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292(19):2350-2356.
• [29]Lacson E, Lazarus JM: The association between blood pressure and mortality in ESRD-not different from the general population? Semin Dial 2007, 20(6):510-517.
• [30]Bakris G: Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010, 105(1 Suppl):21A-29A.
• [31]Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H, Suzuki H: Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004, 43(3):380-386.
• [32]Furgeson SB, Chonchol M: Beta-blockade in chronic dialysis patients. Semin Dial 2008, 21(1):43-48.
• [33]Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106(15):1974-1979.
• [34]Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327(27):1912-1918.
• [35]Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004, 164(22):2465-2471.
• [36]Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A: Dilated cardiomyopathy in dialysis patients–beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001, 37(2):407-411.
• [37]Quan A: Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Dev 2006, 82(1):23-28.
• [38]Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA: Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002, 15(2):167-184.
• [39]Barbieri A, Bursi F, Mantovani F, Valenti C, Quaglia M, Berti E, Marino M, Modena MG: Prognostic impact of left ventricular mass severity according to the classification proposed by the American Society of Echocardiography/European Association of Echocardiography. J Am Soc Echocardiogr 2011, 24(12):1383-1391.